Physician profile
Max S Scheer
NPI 1134298789
$5,540.88
in general payments reported to CMS, 2019-2025
42 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $770 · 2021: $683 · 2022: $617 · 2023: $628 · 2024: $483 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $849.61 | 2019-2020 | |
| Abbvie INC. | $685.02 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $411.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $371.19 | 2019-2025 | |
| Novo Nordisk INC | $271.32 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $269.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $234.28 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $203.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.08 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $195.13 | 2019-2023 | |
| Genentech USA, INC. | $150.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $149.70 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $143.64 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Esperion Therapeutics, INC. | $126.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $119.89 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Scheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.